When Prophecy Fails

Quick Take: When Prophecy Fails – Cytodyn Edition. (CYDY)

After weeks and weeks of patiently waiting, since the close on the afternoon of Friday the 5th of March, everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY) has issued not one, not two, not three, but six (6!) press releases.

The NaDDiR* has also done a Saturday night pump video, available here. Not one of the press releases has actually given accurate, complete, trial information. All of these appear to have been designed to hide the fact that the CD12 trial of loserlimab in Severe-to-Critical Covid-19 failed miserably. To obfuscate this simple fact, the company has tried to mislead by offering invalid subgroup and sub-subgroup analyses of made-up endpoints. Why invalid? Because the subgroups and the outcomes were not pre-specified. The FDA has correctly rejected these as the basis for any sort of approval or EUA decision.

For those obstinate cult members who refuse to accept and understand this truth, the last of the press releases buried this gem:

Rejected by all three agencies, and forced to complete a new study. Hint: This doesn’t happen if the old study was a success!

On a positive note, the company finally admits that they did not do an Open Label Extension to the CD12 trial, rather they added an Open Label Arm. These are not the same thing. Precision counts when dealing with the regulators. The study records regarding this (see link to CD12 study above) still have not been updated since November 16, 2020, so the truth may never be known.

Are you an angry bagholder, or just someone who still believes the company and its nonsense? Then please, please, please, take a minute and buy this book from Amazon which is conveniently on sale for just $0.99. When Prophecy Fails, by Festinger, may help you avoid such tragedies in the future.

If only there would be live Q&A on the CONference call tonight.

The Klown Krew is smart enough to avoid that. Instead expect them to offer pre-written platitudes and spin from pre-planned “questions.”

Perhaps after the CONference call we can get into the weeds and discuss the failure of Cytodyn to correct for multiple comparisons. This why the p-values given for the results in the post-hoc subgroups are invalid. We can explore the mysterious disappearance of 10 patients from the trial. And we can examine the even more curious disappearance of 7 deaths from the trial. Either loserlimab really can reanimate the dead, or the Cytoklowns can’t count very well. Our guess? The latter.

* Spelled Thusly For A Double Dose of That Sweet Sweet Stock Pimping

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.